Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 74Carcinoma, Non-Small-Cell Lung 73Breast Neoplasms 39Lung Neoplasms 31Urinary Bladder Neoplasms 28Nasopharyngeal Carcinoma 28Ovarian Neoplasms 25Neoplasm Metastasis 21Cholangiocarcinoma 18Triple Negative Breast Neoplasms 16Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Gallbladder Neoplasms 13Biliary Tract Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Carcinoma, Transitional Cell 12Nasopharyngeal Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 9Lymphoma 7Carcinoma 7Bile Duct Neoplasms 7Lymphoma, Non-Hodgkin 6Adenocarcinoma 6Carcinoma, Hepatocellular 5Adenocarcinoma of Lung 5Neoplasms by Site 4Urothelial Cancer 3

Interventions

Radiotherapy 3Pyridoxine 2Etoposide 2Epoetin Alfa 2Cisplatin 2Capecitabine 2uridine triacetate 1peginterferon alfa-2b 1pegaspargase 1Vincristine 1Pyridostigmine Bromide 1Prednisolone 1Paclitaxel 1Oxaliplatin 1Octreotide 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Laparoscopy 1Introns 1Hydrocortisone 1Gemcitabine 1Furosemide 1Fluorouracil 1Filgrastim 1Erythropoietin 1Duloxetine Hydrochloride 1Doxorubicin 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Drug-Related Side Effects and Adverse Reactions × Gemcitabine × Clear all
NCT00024427 2012-06-28

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Wellstat Therapeutics

Phase 3 Completed
250 enrolled
Gastrointestinal

Pancreatic Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡